$-0.46 EPS Expected for Viveve Medical, Inc. (VIVE)

February 14, 2018 - By Kurt Siggers

 $ 0.46 EPS Expected for Viveve Medical, Inc. (VIVE)

Analysts expect Viveve Medical, Inc. (NASDAQ:VIVE) to report $-0.46 EPS on February, 15.They anticipate $0.09 EPS change or 16.36 % from last quarter’s $-0.55 EPS. After having $-0.50 EPS previously, Viveve Medical, Inc.’s analysts see -8.00 % EPS growth. The stock decreased 3.53% or $0.16 during the last trading session, reaching $4.37. About 568,946 shares traded or 175.58% up from the average. Viveve Medical, Inc. (NASDAQ:VIVE) has risen 5.85% since February 14, 2017 and is uptrending. It has underperformed by 10.85% the S&P500.

Viveve Medical, Inc. designs, develops, makes, and markets medical devices for the non-invasive treatment of vaginal laxity. The company has market cap of $128.56 million. The firm offers Geneveve, a non-invasive solution that includes the Viveve System, a radio frequency generator; a reusable hand piece and single-use treatment tip; and other consumable accessories. It currently has negative earnings. It markets its products through sales employees and distributors in Asia, Europe, the Middle East, Latin America, the United States, Canada, and internationally.

More notable recent Viveve Medical, Inc. (NASDAQ:VIVE) news were published by: Streetinsider.com which released: “Viveve Medical (VIVE) Prices 10M Share Common Offering at $3/Sh” on February 07, 2018, also Marketwired.com with their article: “Viveve Announces Closing of Public Offering of Shares of Common Stock” published on February 12, 2018, Streetinsider.com published: “Viveve Medical (VIVE) to Offer Common Stock” on February 07, 2018. More interesting news about Viveve Medical, Inc. (NASDAQ:VIVE) were released by: Marketwired.com and their article: “Viveve Announces Proposed Public Offering of Shares of Common Stock” published on February 07, 2018 as well as Seekingalpha.com‘s news article titled: “Viveve Medical’s CMRF shows positive effect in stress urinary incontinence study” with publication date: January 31, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: